Isomorphic Labs closes a $5 billion Series C to push AI-designed drug candidates toward clinical trials
Synopsis
Isomorphic Labs announced a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with new investors including a16z, continued large investment from Alphabet, and participation from all existing investors. The company says the capital will further mature its in-house drug design engine IsoDDE, expand its internal and partnered candidate pipeline, and build AI-oriented infrastructure for translational and clinical development so candidates can move into clinical trials. The company also reports positive preclinical results in internal oncology and immunology programs and in partnered projects.
Interpretation
Isomorphic Labs has raised a $5 billion Series C to advance its AI drug design engine and candidate pipeline. The company had been advancing through its in-house engine and partnership programs; this round concentrates resources on maturing the engine, expanding the pipeline and building clinical-translation infrastructure. The round was co-led by Greenoaks and Sequoia Capital, with a16z and other new investors participating, continued significant investment from Alphabet, and participation from all existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund; the company describes the round as oversubscribed.
The central destination for the capital is the in-house drug design engine IsoDDE, which combines a set of fundamental simulation AI models usable across multiple therapeutic areas and drug classes. These models explore vast chemical spaces so the team can design, refine and deliver precisely constructed molecules with optimal drug-like properties; the company says the breadth and precision of its simulation models bring predictions close to the accuracy of experimental results. The company says that combined with proprietary algorithms these models repeatedly drive progress in its multimodal candidate pipeline and have produced positive preclinical results in internal oncology and immunology programs and in partnered projects, paving the way to the clinical stage.
Perspective
This report covers Isomorphic Labs' financing announcement and the company's description of its engine and pipeline, for researchers and engineers following AI drug discovery; the company says the capital will move candidates toward clinical trials but gives no specific timeline.
Preclinical results are described only as positive, with no specific metrics, sample sizes or controls; the claim that predictions approach experimental accuracy comes without a quantitative comparison; entry into the clinical stage is described as paving the way rather than as trials already under way.
